Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DCL000170

Drug Information
NameMLN8237    
CompanyTakeda & Millennium    
IndicationAcute myelogenous leukemia, High-risk myelodysplastic syndrome and Ovarian cancerPhase II    
Advanced solid tumours and haematological malignanciesPhase I    
Paediatric solid tumours or ALLPhase I/II    
Therapeutic ClassAntineoplastic Agents    
ClinicalTrials.govNCT00500903;    
NCT00739427;    
NCT00830518;    
TargetAurora A kinaseInhibitor[1]
Ref 1Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553 To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543